NCT04767815已完成1 期
A Randomized, Open-label, Single Dose, Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics and Safety After Oral DWN12088 Administration in Healthy Adult Volunteers
Daewoong Pharmaceutical Co. LTD.1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2021年3月22日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Cmax of DWN12088 and metabolite
研究概览
简要总结
The pharmacokinetics (PK) and safety of single oral dose of DWN12088 in healthy adults will be compared and assessed on an empty stomach, after high-fat meal, or 2 hours after high-fat meal.
详细描述
The pharmacokinetics and safety of single oral dose of DWN12088 in healthy adults will be compared and assessed on an empty stomach, after high-fat meal, or 2 hours after high-fat meal.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adults aged ≥ 19 and ≤ 55 years at screening
- •Subjects with body weight ≥ 55.0 kg (male) or ≥ 45.0 kg (female) with a body mass index (BMI) of ≥ 18.0 kg/m2 to < 27.0 kg/m2 at screening test
- •☞ BMI (kg/m2) = Body weight (kg) / {Height (m)}2
- •Subjects who have given written consent on voluntary decision of participation prior to the screening procedure after being fully informed of and completely understanding this study
排除标准
- •Subjects with current or history of clinically significant hematological disorder, tumor, or immunologic, endocrine, psychiatric, neurological, cardiovascular, respiratory, digestive, hepatobiliary, renal, or urinary disorder
- •Subjects with a history of a gastrointestinal disorder (gastrointestinal ulcers, gastritis, stomach cramps, gastroesophageal reflux disease, Crohn's disease, etc.) or surgery (except for simple appendectomy or hernia surgery) that may affect the safety and PK assessment of the investigational product (IP)
- •Subjects with clinically significant hypersensitivity to any drugs including the ingredient of the IP (DWN12088) or excipients
- •Subjects determined ineligible for meeting the one of the following on the screening tests conducted within 28 days prior to administration of the IP administration
- •① AST or ALT > 1.5 times the upper limit of normal
- •Estimated glomerular filtration rate (eGFR) < 90 mL/min/1.73 m2 based on the modification of diet in renal disease (MDRD) formula ③ QTc interval > 450 ms ④ Positive result in serology (hepatitis B tests, hepatitis C tests, human immunodeficiency virus [HIV] tests, syphilis tests) ⑤ Sitting systolic blood pressure > 150 mmHg or < 90 mmHg or sitting diastolic blood pressure > 100 mmHg or < 50 mmHg after resting for more than 3 minutes
- •Subjects with a history of drug abuse or positive result of using abusive drugs in urine drug screening test within 1 year prior to screening
- •Subjects who used any prescription drugs or herbal medicines within 14 days, or any over-the-counter (OTC) drugs including dietary supplements and vitamin supplements within 7 days prior to the first dose of the IP which are judged to impact the study or the subject's safety by the investigator
- •Subjects who participated in another clinical study and received another IP within 180 days before the first dose of the IP
- •Subjects who donated whole blood within 60 days, donated blood components within 30 days, or received blood transfusion within 30 days prior to the first dose of the IP
- •Subjects who consistently consumed excessive amount of caffein or alcohol (caffein > 5 cups/day, alcohol > 210 g/week) or are unable to refrain from caffein or alcohol intake from 3 days before the first dose to the post study visit (PSV)
- •Subjects who are current smokers (may be selected as subjects if they stopped smoking more than 180 days prior to the first dose of the IP) or unable to stop smoking from 180 days prior to the first dose of the IP to the PSV
- •Subjects who used drugs inducing and inhibiting drug-metabolizing enzymes, such as barbital drugs, within 30 days prior to the first dose of the IP
- •Subjects who consumed grapefruit, grapefruit juice, or grapefruit-containing products from 3 days prior to the first hospitalization to the last discharge of period 3, or are unable to refrain from the intake of grapefruit-containing products during this period
- •Subjects who are on or plan to receive CYP2D6 inducing/inhibiting drugs
- •Female subjects who are pregnant or lactating
- •① All female subjects with childbearing potential except for those who are menopausal or surgically sterile (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), who have a positive pregnancy test (serum hCG or urine hCG)
- •Subjects or their spouses or partners who are unable to use medically acceptable appropriate double-method of contraception or medically acceptable contraception throughout the study period and for at least 4 weeks after the last IP administration, and disagreed to refrain from donating sperms during this period
- •Caution: Woman of childbearing potential is defined as a woman who is not surgically sterile or post-menopausal. Women amenorrhoeic for 12 months without an alternative medical cause will be considered as post-menopausal.
- •Medically acceptable methods of contraception ① Use of intrauterine device (except for copper banded coil and hormonal device) for which pregnancy failure rate is proven, by a subject or spouse (or partner) ② Physical and chemical barrier contraception (male/female condom with spermicide, diaphragm, sponge, cervical cap with spermicide, etc.) ③ Surgical sterilization (vasectomy, salpingectomy, tubal ligation, and hysterectomy) of a subject or spouse (or partner)
- •Subjects determined to be ineligible to participate in the study by the investigator due to reasons other than those specified above
研究组 & 干预措施
Sequence 5
Experimental
- Period 1: C (2 hours after a High-fat meal)
- Period 2: B (30 minutes after a High-fat meal)
- Period 3: A (Fasting)
干预措施: Diet B group (Drug)
Sequence 5
Experimental
- Period 1: C (2 hours after a High-fat meal)
- Period 2: B (30 minutes after a High-fat meal)
- Period 3: A (Fasting)
干预措施: Diet C group (Drug)
Sequence 1
Experimental
- Period 1: A (Fasting)
- Period 2: B (30 minutes after a High-fat meal)
- Period 3: C (2 hours after a High-fat meal)
干预措施: Diet A group (Drug)
Sequence 1
Experimental
- Period 1: A (Fasting)
- Period 2: B (30 minutes after a High-fat meal)
- Period 3: C (2 hours after a High-fat meal)
干预措施: Diet B group (Drug)
Sequence 1
Experimental
- Period 1: A (Fasting)
- Period 2: B (30 minutes after a High-fat meal)
- Period 3: C (2 hours after a High-fat meal)
干预措施: Diet C group (Drug)
Sequence 2
Experimental
- Period 1: B (30 minutes after a High-fat meal)
- Period 2: C (2 hours after a High-fat meal)
- Period 3: A (Fasting)
干预措施: Diet A group (Drug)
Sequence 2
Experimental
- Period 1: B (30 minutes after a High-fat meal)
- Period 2: C (2 hours after a High-fat meal)
- Period 3: A (Fasting)
干预措施: Diet B group (Drug)
Sequence 2
Experimental
- Period 1: B (30 minutes after a High-fat meal)
- Period 2: C (2 hours after a High-fat meal)
- Period 3: A (Fasting)
干预措施: Diet C group (Drug)
Sequence 3
Experimental
- Period 1: C (2 hours after a High-fat meal)
- Period 2: A (Fasting)
- Period 3: B (30 minutes after a High-fat meal)
干预措施: Diet A group (Drug)
Sequence 3
Experimental
- Period 1: C (2 hours after a High-fat meal)
- Period 2: A (Fasting)
- Period 3: B (30 minutes after a High-fat meal)
干预措施: Diet B group (Drug)
Sequence 3
Experimental
- Period 1: C (2 hours after a High-fat meal)
- Period 2: A (Fasting)
- Period 3: B (30 minutes after a High-fat meal)
干预措施: Diet C group (Drug)
Sequence 4
Experimental
- Period 1: A (Fasting)
- Period 2: C (2 hours after a High-fat meal)
- Period 3: B (30 minutes after a High-fat meal)
干预措施: Diet A group (Drug)
Sequence 4
Experimental
- Period 1: A (Fasting)
- Period 2: C (2 hours after a High-fat meal)
- Period 3: B (30 minutes after a High-fat meal)
干预措施: Diet B group (Drug)
Sequence 4
Experimental
- Period 1: A (Fasting)
- Period 2: C (2 hours after a High-fat meal)
- Period 3: B (30 minutes after a High-fat meal)
干预措施: Diet C group (Drug)
Sequence 5
Experimental
- Period 1: C (2 hours after a High-fat meal)
- Period 2: B (30 minutes after a High-fat meal)
- Period 3: A (Fasting)
干预措施: Diet A group (Drug)
Sequence 6
Experimental
- Period 1: B (30 minutes after a High-fat meal)
- Period 2: A (Fasting)
- Period 3: C (2 hours after a High-fat meal)
干预措施: Diet A group (Drug)
Sequence 6
Experimental
- Period 1: B (30 minutes after a High-fat meal)
- Period 2: A (Fasting)
- Period 3: C (2 hours after a High-fat meal)
干预措施: Diet B group (Drug)
Sequence 6
Experimental
- Period 1: B (30 minutes after a High-fat meal)
- Period 2: A (Fasting)
- Period 3: C (2 hours after a High-fat meal)
干预措施: Diet C group (Drug)
结局指标
主要结局
Cmax of DWN12088 and metabolite
时间窗: Day 1, Day8 and Day15 of 0 hours, 0.5 hours, 1 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours
To evaluate pharmacokinetics parameter
AUClast of DWN12088 and metabolite
时间窗: Day 1, Day8 and Day15 of 0 hours, 0.5 hours, 1 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours
To evaluate pharmacokinetics parameter
Adverse events (AEs) such as subjective and objective symptoms
时间窗: follow-up 26 days after dosing
To evaluate safety
次要结局
- AUCinf of DWN12088 and metabolite(Day 1, Day8 and Day15 of 0 hours, 0.5 hours, 1 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours)
- Tmax of DWN12088 and metabolite(Day 1, Day8 and Day15 of 0 hours, 0.5 hours, 1 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours)
- t1/2 of DWN12088 and metabolite(Day 1, Day8 and Day15 of 0 hours, 0.5 hours, 1 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours)
- Vd/F of DWN12088 and metabolite(Day 1, Day8 and Day15 of 0 hours, 0.5 hours, 1 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours)
- CL/F of DWN12088 and metabolite(Day 1, Day8 and Day15 of 0 hours, 0.5 hours, 1 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP14012 After Oral Administration in Healthy Japanese, Caucasian and KoreanHealthy VolunteersNCT03574415Daewoong Pharmaceutical Co. LTD.80
已完成
1 期
Evaluate the Pharmacokinetics and Safety of DWP14012 Tablet A and Compare Those of DWP14012 Tablet B in Healthy SubjectsPhase 1 Study, Healthy VolunteersNCT05149274Daewoong Pharmaceutical Co. LTD.32
Unknown
1 期
Pharmacokinetics of Besifovir in Adults With Normal and Impaired Renal FunctionRenal ImpairmentNCT04249908IlDong Pharmaceutical Co Ltd40
已完成
1 期
A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal ImpairmentHepatic ImpairmentRenal ImpairmentNCT05112419AstraZeneca12
Unknown
1 期
Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy VolunteersAdvanced Solid TumorsNCT03641794Jiangxi Qingfeng Pharmaceutical Co. Ltd.56